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Expression of microRNAs in cerebrospinal 
fluid of dogs with central nervous system 
disease
Katia Marioni‑Henry1* , Debiao Zaho1, Pablo Amengual‑Batle2, Nina Marie Rzechorzek1,3  
and Michael Clinton1
Abstract 
In this pilot study we investigated the expression of 14 microRNAs in the cerebrospinal fluid (CSF) of dogs with neo‑
plastic, inflammatory and degenerative disorders affecting the central nervous system (CNS). CSF microRNA (miRNA) 
expression profiles were compared to those from dogs with neurological signs but no evidence of structural or 
inflammatory CNS disease. Seven miRNAs were easily detected in all samples: miR‑10b‑5p, miR‑19b, miR‑21‑5p, miR‑
30b‑5p, miR‑103a‑3p, miR‑124, and miR‑128‑3p. Expression of miR‑10b‑5p was significantly higher in the neoplastic 
group compared to other groups. There was no relation between miRNA expression and either CSF nucleated cell 
count or CSF protein content. Higher expression of miR‑10b‑5p in the neoplastic group is consistent with previous 
reports in human medicine where aberrant expression of miR‑10b is associated with various neoplastic diseases of 
the CNS.
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Findings
MicroRNAs (miRNAs) are a class of small, non-coding 
RNAs of approximately 20–25 nucleotides in length that 
regulate gene expression at the post-transcriptional level 
[1]. MicroRNA molecules are extremely stable and miR-
NAs expressed in neurons can be found in cerebrospinal 
fluid (CSF) and serum [2]. For central nervous system 
(CNS) disorders, proximity to the diseased tissue and low 
cellular content make CSF the preferred fluid for analyses 
[1–3].
In human medicine, miRNAs in CSF have been con-
sidered as potential biomarkers for the early diagnosis 
and prognosis of various CNS neoplastic, inflammatory 
and degenerative diseases (e.g. gliomas, glioblastomas, 
metastatic brain tumours, multiple sclerosis, amyo-
trophic lateral sclerosis, Alzheimer’s disease and Parkin-
son’s disease) [1, 2, 4]. Recently, expression of miR-21 and 
miR-181c in the CSF of dogs with meningoencephalitis of 
unknown origin (MUO) has been reported [5].
The primary aim of this pilot study was to assess the 
expression of 14 miRNAs in CSF samples of dogs that 
underwent a diagnostic work-up for investigation of neu-
rological signs. The secondary aim was to compare the 
miRNA profiles of dogs diagnosed with structural CNS 
disorders (i.e. inflammatory, neoplastic, and degenera-
tive conditions affecting brain, spinal cord and meninges; 
see groups A, B and D in Table 1, which were combined 
for this comparison) to those of dogs without evidence 
of structural CNS disease (combined groups C and E); 
this second group included dogs with epilepsy but no 
evidence of a specific underlying cause (i.e. idiopathic 
epilepsy group C in Table  1) and dogs with neurologi-
cal signs localised to peripheral nerves only (group E). A 
tertiary aim was to compare the expression of the miR-
NAs in CSF samples of dogs in each of the five groups 
listed in Table 1. The selection of the miRNAs was based 
on similar studies performed in human medicine that 
identified dysregulation of these 14 miRNAs in a variety 
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of CNS neoplastic, inflammatory and degenerative dis-
eases. Teplyuk et al. [6] reported increased levels of miR-
10b and miR-21 in the CSF of patients with glioblastoma 
and brain metastasis of breast and lung cancer, compared 
with tumors in remission and a variety of non-neoplastic 
conditions; miR-21 and miR-19b were among the most 
highly upregulated miRNA in primary CNS lymphoma; 
miR-181c and miR-633 miR-128-3p miR-155-5p were 
upregulated in multiple sclerosis, dysregulation of miR-
210 and MiR-922 miR-103a-3p miR-194-5p was reported 
in degenerative conditions [7] and dysregulation of 
miR146, miR155 and miR124 in epilepsy [8, 9].
The study was conducted in compliance with the guide-
lines of the Veterinary Ethical Review Committee of the 
Royal (Dick) School of Veterinary Studies of the Univer-
sity of Edinburgh (Approval Number 124.17; 20 Novem-
ber 2017). All animals were examined by a board-certified 
neurologist, and diagnoses were based on a combination 
of two or more of the following: clinical findings, mag-
netic resonance imaging (MRI), CSF analysis, and post-
mortem examination (Table 1).
CSF collected via cerebellomedullary cisternal or lum-
bar puncture was centrifuged and the supernatant was 
frozen within 60 min of collection and stored at − 80 °C 
until further use. All samples were visually inspected and 
pink, red, or xanthochromic samples were excluded. CSF 
analysis and cytology was available for 17/20 samples 
(Table 2).
RNA was isolated from a minimum of 250  µL and a 
maximum of 500 µL of CSF. RNA extraction and cDNA 
synthesis were performed using miRCURY LNA Uni-
versal RT microRNA PCR Starter Kit (Exiqon). Syn-
thetic exogenous spike-in UniSp6 RNA was added into 
each sample. Real-time quantitative PCR (qRT-PCR) 
analysis was performed using the ExiLENT SYBR Green 
master mix (Exiqon) and the Stratagene Mx3000P 
Table 1 Clinical data for inflammatory condition group (A), neoplastic condition group (B), idiopathic epilepsy group (C), 
degenerative condition group (D), and other neurological disorders not affecting the CNS group (E)
SOD1: Canine degenerative myelopathy is a progressive neurodegenerative disease associated with the c.118G > A substitution in exon 2 of the canine superoxide 
dismutase 1 (SOD1) gene in German Shepherd Dogs and other affected canine breeds
FE female entire, FN female neutered, ME male entire, MN male neutered
a  Diagnosis supported by histopathology
b  Diagnosis supported by clinical examination, MRI findings, CSF analysis and cytology
Case Signalment Final diagnosis
Breed Age (years) Sex
A Bernese Mountain Dog 1 FN Steroid‑responsive meningitis‑arteritis
A Medium size mixed breed 9 MN Idiopathic polyradiculoneuritis
A Bichon Frise 2 FN Meningoencephalitis of unknown origin
A Dalmatian 0.5 FE Steroid‑responsive meningitis‑arteritis
B American Bulldog cross 9 ME Mixed glioma—braina
B Miniature Schnauzer 7 ME Suspected histiocytic sarcoma—braina
B Flat Coat Retriever 8 MN Histiocytic sarcoma—lumbar spinal  corda
B Boxer 6 FN Glioma—brain
C Labrador Retriever 2 FN Idiopathic epilepsy
C Collie cross 8 FN Idiopathic epilepsy
C Collie 3 MN Idiopathic epilepsy
C Staffordshire Bull Terrier cross 7 FN Idiopathic epilepsy
C Giant Schnauzer 7 FN Idiopathic epilepsy
C Bearded Collie 6 FN Idiopathic epilepsy
D German Shepherd Dog 4 MN Canine degenerative myelopathy—SOD1 homozygous
D German Shepherd Dog 10 FN Canine degenerative myelopathy—SOD1  homozygousa
E Cavalier King Charles Spaniel 6 FN Vestibular signs associated with otitis media‑internab
E Border Collie 14 FN Geriatric idiopathic vestibular  diseaseb
E Labrador Retriever 12 FE Geriatric idiopathic vestibular  diseaseb
E Border Terrier 9 MN Iliopsoas  sarcomaa
Page 3 of 6Marioni‑Henry et al. Acta Vet Scand           (2018) 60:80 
real-time quantitative PCR system (Life Technologies). 
Relative expression was calculated as fold-change by 
the ΔΔCt method with UniSp6 as a reference followed 
by normalisation to the expression for sample C4 (con-
trol with idiopathic epilepsy) and to the volume of CSF 
available.
Cycle threshold (Ct) values are inverse to the quan-
tity of target nucleic acid in the sample and high Ct 
values (above 35 cycles) can also be generated by deg-
radation of the probe-based fluorophore by nonspe-
cific amplification of background nucleic acids [10]. 
Accordingly, only  Ct values < 32 were considered reli-
able and only miRNAs with  Ct < 32 in the majority of 
samples were included in subsequent analyses. Analy-
sis of variance (ANOVA) was used to determine if the 
expression of each miRNA differed among dogs with 
and without CNS structural disease and then among 
the five categories of disease (Table  1). A general lin-
ear model (GLM) was used to assess the relationship 
between CSF nucleated cell count and miRNA expres-
sion, and CSF protein content and miRNA expression. 
All statistical analyses were conducted with R version 
3.2.2 [(2015–08–14) 2015, The R Foundation for Sta-
tistical Computing].
Seven miRNAs were amplified in all samples: miR-
10b-5p, miR-19b, miR-21-5p, miR-103a-3p, miR-124, 
and miR-128-3p. The remaining seven miRNAs were 
not detected  (Ct ≥ 32 in ≥ 50% of the samples): miR-146, 
miR-155-5p, miR-181c, miR-194-5p, miR-210, miR-633, 
and miR-922.
Expression of miR-10b-5p was significantly (P= 0.028), 
higher (mean 4.51 ± 0.79 SD, n = 10) in the group of 
dogs with CNS disease (combined groups A, B and D) 
compared to dogs without evidence of CNS structural 
disease (combined groups C and E; mean 2.28 ± 0.52 
SD, n = 10). Expression of miR-10b-5p was also sig-
nificantly (P= 0.008) higher in the neoplastic group (B) 
when compared to all other groups (Figs. 1, 2). No other 
significant differences in miRNA expression between 
groups were detected. However, the expression of miR-
128 approached significance with a probability level of 
P = 0.074 in the idiopathic epilepsy group (C) when com-
pared to all other groups (Figs. 1, 2).
No significant correlation (P > 0.05, GLM) was detected 
between CSF nucleated cell count and miRNA expres-
sion, or CSF protein content and miRNA expression.
Higher expression of miR-10b-5p in the neoplastic 
group is consistent with previous reports in human med-
icine; levels of both miR-10b and miR-21 were signifi-
cantly increased in the CSF of patients with glioblastoma 
and brain metastasis of breast and lung cancer compared 
with tumours in remission and a variety of non-neoplas-
tic conditions, while miR-10b was not detected in brain 
or CSF of non-cancer human patients [6].
A recent study investigating the expression of miR-
21 and miR-181c in the CSF of dogs with MUO, found 
that the expression of miRNAs in the CSF, particularly 
miR-21, was correlated with the CSF nucleated cell 
count [5]. This finding was not replicated in our study 
using a GLM, possibly due to the low average nucleated 
cell count and the small sample size of this pilot study. 
In our study, the CSF samples were visually inspected 
prior to analysis and those presenting a reddish or xan-
thochromic discoloration were excluded to avoid con-
tamination from peripheral blood. Therefore, acute 
forms of steroid responsive meningitis-arteritis (SRMA) 
associated with a high nucleated cell count and xan-
thochromic CSF would have been excluded by this study 
(Table  2). However, whilst highly inflammatory CSF 
samples do not pose a diagnostic challenge for SRMA, 
Table 2 Cerebrospinal fluid analysis (normal laboratory reference range for nucleated cells ≤ 5 cells/μL and for protein 
concentration ≤ 0.25 mg/dL for cisternal samples and ≤ 0.45 mg/dL for lumbar samples)





Inflammatory (group A) 4/4 1.1 2/4 rare 11.25
Neoplastic (group B) 2/4 4.4 Rare and moderate 
numbers
122
Idiopathic epilepsy (group C) 6/6 1.1 None 18.8
Canine degenerative myelopathy (group D) 2/2 2 None 20
Neurological signs not localised to CNS or meninges 
(group E)
3/4 0 None 30.6
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chronic SRMA cases can present with normal or only 
slightly elevated CSF protein content and mild pleocy-
tosis [11, 12]. For more than 20  years researchers have 
been looking for biomarkers to improve the diagnostic 
and prognostic accuracy of SRMA [11, 12]. Based on our 
results, we believe that further studies investigating the 
use of upregulated miRNAs as biomarkers for chronic 
SRMA are warranted. For similar reasons, we decided 
to include cases of acute idiopathic polyradiculoneuri-
tis (AIP) in our study. In the first instance, canine AIP 
is an inflammatory condition of the ventral nerve roots 
and peripheral nerves analogous to Guillain–Barré syn-
drome in humans where presence of CNS inflammation 
has been demonstrated by immunohistochemistry [13, 
14]. Secondly, like chronic SRMA, canine AIP is diag-
nostically challenging since it presents with abnormal 
CSF analysis characterized by nonspecific elevated pro-
tein content and normal nucleated cell count [13]. Our 
primary objective was therefore to investigate the pos-
sibility of detecting upregulated miRNAs in the CSF of 
AIP cases as potentially useful diagnostic biomarkers.
The major limitations of this pilot study were the low 
sample size and the lack of a true control group of dogs 
without neurological signs; this to comply with UK legis-
lation that requires that any medical procedure involving 
client-owned dogs must be performed for the direct ben-
efit of the patient. Studies performed on human patients 
face similar limitations in regard to control groups, how-
ever, CSF is still considered the ideal source of miRNA 
to investigate brain disorders in human patients, due to a 
profile identical to that of the brain tissue and a less inva-
sive and more accessible procedure compared to a brain 
biopsy [7].
Conclusions
The expression of 14 miRNAs in the CSF of dogs with 
neurological disorders with and without structural CNS 
abnormalities showed that 7 miRNAs were consistently 
expressed in all samples. We also found a significantly 
increased expression of miR-10b-5p in the neoplastic 
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miR 30b-5p
Fig. 1 Relative expression of microRNA‑10b‑5p (miR‑10b‑5p), 
microRNA‑19b (miR‑19b), microRNA‑21b‑5p (miR‑21b‑5p), 
microRNA‑30b‑5p (miR‑30b‑5p) in cerebrospinal fluid (CSF) of dogs 
with inflammatory conditions (group A), neoplastic conditions (group 
B), idiopathic epilepsy (group C), degenerative conditions (group D), 
and other neurological disorders not affecting the CNS (group E). Error 
bars represent the standard error. *Statistically significant difference 
between groups (*P = 0.008)
◂
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If our findings are replicated in a larger cohort, CSF 
miRNA expression analysis may prove to be a useful, 
minimally invasive technique to support the pre-mortem 
diagnosis of CNS disorders in dogs.
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miR 128-3p
Fig. 2 Relative expression of microRNA‑103a‑3p (miR‑103a‑3p), 
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